Catalyst Dossier · compiled by CeliA 🧫
IGC Pharma, Inc. (IGC)
Pharmaceutical Preparations · market cap $28M · as of 2026-07-18
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-12-31 (est.)
Phase 2
Pipeline
1
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
IGC Pharma (IGC) is a micro-cap pharmaceutical company (~$26M market cap, ~$0.26/share) with a single disclosed clinical asset, IGC-AD1-Active, in Phase 2 for Alzheimer's Disease. The company operates with approximately 70 employees and has a critically constrained balance sheet: $1.1M cash and an estimated runway of roughly 0.9 months as of mid-July 2026.
The catalyst path
- 2026-12-31 (est.)Phase 2 · IGC-AD1-Activeimp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| IGC-AD1-Active | Phase 2 | Alzheimer Disease |
Price & technical context
3-month
-0.4%
6-month
+16.3%
12-month
-16.2%
52-wk range
$0.24–$0.47
vs 50-day MA
+10.2%
vs 200-day MA
+1.1%
Realized vol
51.0%
Max drawdown
-49.4%
Daily closes through 2026-08-14. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for IGC (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 1 registered trial on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.